15.75

0.25% -0.04

Pre-market: 15.75

Entrada Therapeutics Inc (TRDA)

Overview News Price History Financials Discussions Forecast

Entrada Therapeutics Inc stock is traded at $15.75, with a volume of 401.99K. It is down -0.25% in the last 24 hours and up +19.77% over the past month. Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Previous Close:

$15.79

Open:

$15.82

24h Volume:

401.99K

Relative Volume:

1.95

Market Cap:

$611.42M

Revenue:

$25.42M

Net Income/Loss:

$-143.75M

P/E Ratio:

-4.5377

EPS:

-3.4709

Net Cash Flow:

$-129.55M

1W Performance:

+22.19%

1M Performance:

+19.77%

6M Performance:

+126.95%

1Y Performance:

+73.27%

1-Day Range:

$14.81

$16.19

1-Week Range:

$12.41

$16.19

52-Week Range:

$4.93

$16.19

Entrada Therapeutics Inc Stock (TRDA) Company Profile

Name

Entrada Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

857-305-1825

Address

ONE DESIGN CENTER PLACE, BOSTON

Employee

152

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

TRDA's Discussions on Twitter

Compare TRDA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TRDA Entrada Therapeutics Inc	15.75	611.42M	25.42M	-143.75M	-129.55M	-3.4709
VRTX Vertex Pharmaceuticals Inc	424.36	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.06B	5.36B	287.73M	924.18M	2.5229

Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-01-26	Initiated	Cantor Fitzgerald	Overweight
Feb-11-26	Initiated	Guggenheim	Buy
Jan-28-26	Initiated	Oppenheimer	Outperform
Dec-06-24	Initiated	ROTH MKM	Buy
Jan-05-24	Initiated	Oppenheimer	Outperform
Apr-03-23	Initiated	H.C. Wainwright	Buy

View All

Entrada Therapeutics Inc Stock (TRDA) Latest News

May 05, 2026

Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains? - Yahoo Finance

May 05, 2026

May 04, 2026

Entrada Therapeutics president & COO sells $229,953 in shares By Investing.com - Investing.com Canada

May 04, 2026

Entrada Therapeutics president & COO sells $229,953 in shares - Investing.com

May 04, 2026

Entrada Therapeutics (TRDA) R&D president sells 25,907 shares under 10b5-1 plan - Stock Titan

May 04, 2026

[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity - Stock Titan

May 04, 2026

Entrada Therapeutics R&D president sells $398,809 in shares By Investing.com - Investing.com UK

May 04, 2026

Entrada Therapeutics R&D president sells $398,809 in shares - Investing.com

May 04, 2026

Morgan Stanley Smith Barney files TRDA Form 144; 15,000 shares sold (TRDA) - Stock Titan

May 04, 2026

TRDA (NASDAQ: TRDA) reports 25,907 RSUs to sell; insider sold March 2026 - Stock Titan

May 04, 2026

Entrada Therapeutics Inc expected to post a loss of $1.04 a shareEarnings Preview - TradingView

May 04, 2026

May 01, 2026

Entrada Therapeutics (NASDAQ:TRDA) Reaches New 12-Month HighWhat's Next? - MarketBeat

May 01, 2026

Apr 30, 2026

Entrada Therapeutics (TRDA) Expected to Announce Earnings on Thursday - MarketBeat

Apr 30, 2026

Apr 29, 2026

Is Entrada Therapeutics (TRDA) stock showing strong momentum | Q4 2025: EPS Tops ViewsTrending Social Stocks - Newser

Apr 29, 2026

Apr 26, 2026

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Apr 26, 2026

Apr 24, 2026

Entrada Therapeutics (NASDAQ: TRDA) details 2026 proxy and equity plan changes - Stock Titan

Apr 24, 2026

Apr 23, 2026

Trading Systems Reacting to (TRDA) Volatility - Stock Traders Daily

Apr 23, 2026

TRDA (Entrada Therapeutics) reports narrower Q4 2025 loss than expected, shares edge lower on steep revenue decline.Expert Breakout Alerts - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 23, 2026

Apr 16, 2026